Generic Medicine Info
Indications and Dosage
Uncomplicated gonorrhoea
Adult: 500 mg as a single dose.

Mild to moderate susceptible infections
Adult: 500 or 750 mg every 12 hr.

Prophylaxis of surgical infections
Adult: 1 g may be given on induction of anaesthesia, followed by 1 g 3 hr later, with additional doses of 500 mg at 8 and 16 hr after induction if necessary.

Susceptible infections
Adult: Combined with cilastatin: (as anhydrous imipenem) 1-2 g daily in divided doses every 6-8 hr, given via IV infusion. Doses 250 or 500 mg are infused over 20-30 min, and doses of 750 mg or 1 g over 40-60 min. Max: 4 g/day or 50 mg/kg.
Child: >40 kg: same as adult dose. Child >3 mth and <40 kg: 15-25 mg/kg every 6 hr by IV infusion. Doses up to 90 mg/kg may be given to older children with cystic fibrosis. Neonates and infants <3 mth: 4 wk-3 mth, 25 mg/kg every 6 hr; 1-4 wk, 25 mg/kg every 8 hr; up to 1 wk, 25 mg/kg every 12 hr. Max: >40 kg: 4 g/day or 50 mg/kg; <40 kg: 2 g/day.
Renal Impairment
Susceptible infections: Max doses based on CrCl.
CrCl (mL/min) Dosage
≤5 Only give if haemodialysis is started within 48 hours.
21-30 500 mg every 8-12 hours.
31-70 500 mg every 6-8 hours.
6-20 250 mg or 3.5 mg/kg (whichever is lower) every 12 hours.
Special Precautions
Caution when used in patients with known hypersensitivity to other β-lactams due to possibility of cross-sensitivity. CNS disorders such as epilepsy; renal, hepatic impairment; pregnancy, lactation.
Adverse Reactions
Skin rashes, urticaria, eosinophilia, fever, nausea, vomiting, diarrhoea, tooth or tongue discoloration, and altered taste. Erythema multiforme, exfoliative dermatitis. Pain and thrombophlebitis may occur at the inj site.
Potentially Fatal: Severe anaphylactic reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis.
IM/IV/Parenteral: C
Drug Interactions
Increased risk of seizures when used with ganciclovir. Ciclosporin may increase neurotoxicity of ifosfamide; ifosfamide may also raise serum levels of ciclosporin. Serum levels may be increased by uricosuric agents. May reduce efficacy of valproic acid; monitor.
Mechanism of Action: Imipenem is bactericidal and acts by inhibiting bacterial cell wall synthesis. It has a very broad spectrum of activity in vitro, including activity against Gram-positive and Gram-negative aerobic and anaerobic organisms, and is stable to hydrolysis by β-lactamases.
Distribution: Widely distributed in body tissues and fluids.
Metabolism: Partially hydrolised in the kidneys.
Excretion: In the urine via glomerular filtration and tubular secretion.
Dry powder: Store below 25°C. When reconstituted, satisfactory potency is maintained for 4 hr at room temperature and for 24 hr under refrigeration (5°C). Solutions should not to be frozen.
MIMS Class
Other Beta-Lactams
Disclaimer: This information is independently developed by MIMS based on Imipenem from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in